AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06508138 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 plasmid DNA; TA-HPV vaccinia virus
Description: About 1 month before donating blood, donors are required to come to outpatient clinic once a week to receive the following vaccine series:~Week 1: PVX1 (1 of 3): intramuscular injection (IM) of 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 2: PVX1 (2 of 3): IM 3mg DNA prime with pNGVL4a-Sig/E7(detox)/HSP70 vaccine Week 3: PVX1 (3 of 3): IM TA-HPV vaccinia boost Pause for 2 weeks Peripheral blood collection and possible bone marrow harvest depending on randomization
Study NCT05147103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Intensity Focused Ultrasound
Description: LIFU application using various durations, responses of neuromodulation recorded using TMS and EMG.
Study NCT05455723 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation
Description: Inflation-Deflation Technique Versus Magill Forceps Technique for Nasal Intubation by Video-assisted Laryngoscope
Study NCT04921111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT1000
Description: Recombinant 14 valent human papillomavirus vaccine (6,11,16,18,31,33,35,39,45,51,52,56,58,59) (insect cells)
Study NCT04921111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil®9
Description: Recombinant 9 or 4 valent human papillomavirus vaccine
Study NCT04921111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: aluminium phosphate
Study NCT04921111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil®
Description: Recombinant 4 valent human papillomavirus vaccine
Study NCT05159063 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: Patients scheduled to undergo right heart catheterization (RHC) as their standard of care will be included in the study.~The patient will be positioned supine at 0 degrees with normal restful breathing and patient looking straight up. After the right sternocleidomastoid muscle is identified, internal jugular vein (IJV) will be imaged at the apex of the triangle formed by the sternal and clavicular heads of the muscle. Similarly, the inferior vena cava (IVC) will be imaged at the caudal end of the sternum. The diameters of both the veins will be noted during normal respiration. The patients will then be asked to sniff and collapsibility of the veins will be noted. No pressure will be applied on the neck. The anticipated duration for image acquisition is between 5 to 10 minutes.~The patients will undergo the scheduled RHC within 1 hour as scheduled.
Study NCT05332613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRE plus SOC
Description: Participants will undergo time restricted eating (TRE) each day for 12 weeks and will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
Study NCT05332613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Participants will be given lifestyle recommendations with respect to diet (500-1000 kcal) and moderate-intensity exercise (30 minutes).
Study NCT05332613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRE
Description: Participants will undergo time restricted eating (TRE) each day for 12 weeks plus 4 extra visits with the registered dietician and repeat Fibroscan, InBody composition scan, and MRI-PDFF.
Study NCT05062070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TolaSure Topical Gel
Description: TolaSure Topical Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
Study NCT05062070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Gel
Description: TolaSure Vehicle Gel is applied once-daily for up to 10 weeks to designated Treatment Area and Suction Blister Area.
Study NCT06216002 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Train of four nerve stimulator
Description: Patient receive nerve stimulation by TOF-scan equipment at recovery room after surgery.
Study NCT05777772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STOP Falls D Educational Intervention
Description: This is one-arm, health-system embedded pragmatic pilot trial
Study NCT06192459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modality physical therapy
Description: Magnetotherapy, low-energy laser, electrotherapy, etc.
Study NCT06192459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined therapy:
Description: Muscle strength and joint mobility training, provided twice a week for a duration of three weeks (with assessment on the second session of the third week), totaling six rehabilitation sessions. Additionally, patients are required to engage in daily home-based rehabilitation. During the hospital-based training sessions, a therapist provides guidance and conducts the training. This process encompasses progressive muscle strength training, manual joint mobilization, and active and passive joint movement training to achieve effective rehabilitation outcomes. Each rehabilitation session in the hospital lasts approximately 30 minutes. For home-based training, patients must follow the therapist's instructions and complete 20-30 minutes of home rehabilitation every day. Modality physical therapy are are carry out as usual.
Study NCT04820491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray
Description: Shoulder x-rays as felt necessary for standard of care of diagnosis of shoulder dislocation and reduction
Study NCT04820491 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Initial evaluation with ultrasound; may also evaluate nearby areas for concern of fracture. Order x- rays after ultrasound as seen fit for other injuries of diagnostic uncertainty.
Study NCT04669392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 70% Ethanol Alcohol
Description: Ethanol, also called ethyl alcohol, grain alcohol, or alcohol, a member of a class of organic compounds that are given the general name alcohols.~Ethanol is a commonly used fixative. Fixation of the inner layers of the tissue depends on the ability of the fixative to diffuse into the tissue. Moreover, Ethanol has antibacterial antifungal, and antiviral properties.~70% Ethanol is the safest concentration because the water that has been mixed into the ethanol slows the drying time, creating a longer contact time. Ethanol needs to have a contact time of at least 10 seconds to kill Staphylococcus aureus and Streptococcus pyogenes. At a 10 second drying time.
Study NCT05242718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl-L-cysteine (NAC)
Description: Health Canada Natural Product Number (NPN) 80056946
Study NCT04954547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subsidy Treatment
Description: Participants will be awarded $50 for reaching the PBF goal at the end of 12 weeks. Regardless of goal-attainment, participants will be reimbursed 50% of approved health-improving expenses up to a cap of $300 in the 12 weeks. The subsidy is voluntary and flexible, with no direct intervention from researchers - participants will submit receipts and simply be reimbursed at the end of the experiment (subject to approval from the research team).
Study NCT04954547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cash Treatment
Description: Participants will be awarded $350 for reaching the PBF goal at the end of 12 weeks.
Study NCT05969873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercise
Description: Patients in this group will be treated with pilates exercise and conventional physical therapy as baseline treatment.
Study NCT05969873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance training
Description: Patients in this group will be treated with balance training and conventional physical therapy as baseline treatment.
Study NCT05052060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A
Description: 19 patients will be treated with pelvic tilt exercises
Study NCT05052060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: 19 patients will be treated with pelvic tilt exercises and facet joint manipulation.
Study NCT05242718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea
Description: Health Canada Natural Product Number (NPN) 80093896
Study NCT05275322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: The Unified Protocol for transdiagnostic treatment of EDs (hereinafter UP) is a transdiagnostic treatment based on emotional regulation published in 2011 by David H. Barlow et al. (Barlow et al., 2011). It consists of eight treatment modules, with five of them being central (mindfulness, cognitive flexibility, countering emotional behaviors, tolerating physical sensations, and emotional exposure).
Study NCT05242718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Health Canada Natural Product Number (NPN) 80043455
Study NCT05242718 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Palmitoylethanolamide
Description: Health Canada Natural Product Number (NPN) 80097472
Study NCT03496636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian tissue transplant
Description: Pieces of previously frozen ovarian cortex will be put in the abdomen laparoscopically, or with mini laparotomy
Study NCT06415409 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Plain water
Study NCT06415409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gatorade
Description: Sport Drink Gatorade
Study NCT06415409 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BodyArmor
Description: Sport Drink BodyArmor
Study NCT06415409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GoodSport
Description: Sport Drink GoodSport
Study NCT05505357 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery omission
Description: For patients who are expected to achieve pathologic complete response after neoadjuvant chemotherapy based on MRI findings, vacuum-assisted biopsy will be performed on the main primary lesion marked with a clip. In case of pCR on vacuum-assisted biopsy specimen, breast surgery will be omitted.
Study NCT04092790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Gate Device (VGD)
Description: A VGD will be applied to one randomly-assigned lower limb. The VGD will be operated constantly (apart from times that the patient is being bathed or undergoing investigations or procedures) providing intermittent stimulations for a maximum of 10 days.
Study NCT05943145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Dance and Movement Training
Description: Dance movement-based sessions including personalized tasks and imagery, mirroring, and inscription, plus warm-up and cool down practices to ensure physical safety
Study NCT05663307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginkgo diterpene lactone meglumine injection
Description: Intravenous injections of Ginkgo diterpene lactone meglumine injection at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
Study NCT05663307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ginkgo diterpene lactone meglumine injection simulation
Description: Intravenous injections of Ginkgo diterpene lactone meglumine injection simulation at a dose of 25 mg (5ml) diluted with 250 ml physiological saline for 14 days plus aspirin at a dose of 100 mg per day for 90 days.
Study NCT05663307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: plus aspirin at a dose of 100 mg per day for 90 days.
Study NCT05663307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: plus aspirin at a dose of 100 mg per day for 90 days.
Study NCT04803669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrument-assisted soft tissue mobilization technique
Description: This technique; It is applied with the help of a tool made of stainless steel. The instrument is rubbed on the skin at an angle of about 30 degrees, creating a massage-like effect on the soft tissue (2 sessions per week and 5 minutes per session, 8 sessions in total for 4 weeks).
Study NCT04803669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
Study NCT04803669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Hotpack, TENS, Ultrasound and Exercise will be applied as conventional treatment methods.
Study NCT06343038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection, 161Tb-SibuDAB,1GBq
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~200 μg / \~125 nM) in saline
Study NCT06343038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection, 177Lu-PSMA-I&T, 1GBq
Description: Intravenous injection via peripheral venous catheter of \~1GBq 161Tb-SibuDAB (\~100 μg / \~65 nM) in saline
Study NCT06343038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection, 161Tb-SibuDAB, Dose Escalation
Description: Intravenous injection via peripheral venous catheter of 161Tb-SibuDAB in saline. The intervention comprises 4 cycles at 6-week intervals.~The 161Tb-SibuDAB entry activity will be calculated based on dosimetry and toxicity data from the first 3 patients in Phase Ia of the study.~The escalated or de-escalated 161Tb-SibuDAB activity for the subsequent 3-patient cohorts will be determined based on the clinical and biochemical safety information and on organ dosimetry results of the entry/previous cohort. Up to 4 escalation or de-escalation steps will be performed.
Study NCT05013658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pressure measurement
Description: pressure measurement with pilot balloon palpation
Study NCT05448404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA-1007
Description: Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-PSMA-1007.
Study NCT05448404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Intravenous injection of dosage of 222-370MBq(6-10mCi) 18F-FDG.
Study NCT05003453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% Palmitoylethanolamide (PEA) sold as Levagen+
Description: A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
Study NCT05003453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.
Study NCT04597307 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: IN.PACT™ Admiral™ Drug Coated Balloon (DCB)
Description: For percutaneous transluminal angioplasty (PTA) in subjects with obstructive disease of the peripheral arteries.
Study NCT05358431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroimaging and electrophysiology
Description: Brain and spinal cord MRI, transcranial magnetic stimulation; Motor Unit Number Estimation, EEG
Study NCT05210634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: THCv
Description: THCv in MCT oil
Study NCT05210634 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: THCv
Description: THCv in MCT oil
Study NCT06427070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irrigating solution
Description: Saline, sodium hypochlorite, chlorohexidine
Study NCT06113224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection T0
Description: 2 blood samples will be taken in addition to the pre-operative check-up.
Study NCT06113224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection T0
Description: 2 blood samples will be taken in addition to the pre-operative check-up.
Study NCT06113224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood collection 6 months
Description: 1 blood sample will be taken 6 months after surgery.
Study NCT06113224 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood collection 6 months
Description: 1 blood sample will be taken 6 months after surgery.
Study NCT06422364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weighted Wearable Blanket provided by Dreamland Baby Co.
Description: All infants will be placed in a weighted wearable blanket, provided by Dreamland Baby Co., and complete a nap polysomnogram.
Study NCT05077462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C52R1M Tab. and C52R2 Tab.
Description: Single oral dose C52R1M(FDC, Valsartan/Amlodipine) 160/5 mg tablet and C52R2(Chlorthalidone) 25 mg tablet taken together
Study NCT05077462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-C52H
Description: Single oral dose AJU-C52(Valsartan/Amlodipine/Chlorthalidone) 160/5/25 mg FDC tablet
Study NCT05162001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg
Description: Disulfiram used qd during nine weeks to observe effects on body weight
Study NCT05059067 — intervention group
Intervention type: DEVICE
Intervention: Direct laryngoscopy for endotracheal intubation
Description: Patients in operative room, intensive care unit and emergency department requiring direct laryngoscopy for endotracheal intubation
Study NCT05096260 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing based SMS/MMS and web content
Description: Our primary framework that will guide the web content is Self-Determination Theory (SDT). SDT differentiates between autonomous (conscious choice and are personally relevant) and controlled behavioral regulation (performed due to pressure or coercion by external or internal forces). Messages that enhance autonomy and perceived competence and are consistent with a person's values and goals will be more effective in changing behavior than messages focusing on external rewards. To link vaccination to broader values and goals, participants will select 3-4 goals from approximately 20 values/goals. Individually tailored messages will link each of these values to vaccination. We will also tailor testimonials based on member values and communication style preference.
Study NCT06458608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality glasses
Description: virtual reality glasses
Study NCT05637203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE (Toward Hope, Recovery, Interpersonal Growth, Values, and Engagement)
Description: THRIVE is an interpersonally focused recovery and care transition program. THRIVE (previously called RELATE in our SAMHSA grants) involves engaging a person during and following acute suicidal crisis in a sequence of interpersonally focused therapeutic tasks. The purpose of THRIVE is to help CSC guests re-build connections and contribute to the world in ways they find personally meaningful, while also transitioning safely to outpatient, community-based care. THRIVE involves a Belonging and Giving Reflections Group while at the CSC, followed by a 4-week, phone-based, recovery and care transition series of coaching calls.
Study NCT06095427 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY06006 (Denosumab Biosimilar)
Description: single dose of 60 mg LY006006 s.c.
Study NCT06095427 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Prolia (Denosumab)
Description: single dose of 60 mg US-Prolia s.c.
Study NCT05637203 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discharge / Safety Planning
Description: * A written safety plan completed with the person~* Mental health appointment scheduled within seven days~* One phone follow-up call within 30 days
Study NCT06303843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transfer with an electric ride-on car
Description: The children in the experimental group will be transported to the operating theatre by a electric ride-on car.
Study NCT06095427 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Prolia
Description: single dose of 60 mg EU-Prolia s.c.
Study NCT04598139 — intervention group
Intervention type: OTHER
Intervention: Study group
Description: The study group uses a web-based medication error notification system
Study NCT04895085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: BinaxNOW Rapid Antigen System
Description: BinaxNOW Rapid Antigen System (Abbott) is a point-of-care, lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in direct anterior nasal (nares) swabs. Internal controls are built into the testing system and results are available in 15 minutes.~The use of the BinaxNOW system is authorized under the Food and Drug Administration's Emergency Use Authorization. The test is allowed for over-the-counter, non-prescription use with or without symptoms. The test may be used with children two years and older with the help of sample collection by an adult, and the test may be self-administered by anyone aged 15 years or more.
Study NCT04908930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-field activity group - Aim 3
Description: Athletes of two new teams at the middle school level to pilot the practice structure intervention and continuously monitor on-field activity with head impact sensors to evaluate the feasibility, acceptability, and sustainability of the practice structure